PIN3 AWORKSITE INFLUENZA VACCINATION PROGRAM IN RUSSIAA COST-BENEFIT ANALYSIS  by Atkov, O et al.
savings for the National Health Found budget in consequence of
inﬂuenza vaccination in proposed population were 23,000 PLN.
CONCLUSION: Reimbursement of inﬂuenza vaccine (Inﬂu-
vac®) in children with malignancies in Poland would be cost
saving for, at least, the National Health Found budget. Further
analysis from social perpactive, including direct non-medical and
indirect costs, should be performed.
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OBJECTIVES: Although most deaths from inﬂuenza occur
among elderly people, all age groups are affected by inﬂuenza
infections. This illness is responsible for signiﬁcant epidemiologi-
cal and economic burden to the working age population. Inﬂu-
enza vaccination has been demonstrated to reduce this impact,
however few information concerns Eastern Europe countries.
This study was designed to determine the effectiveness of inﬂu-
enza vaccination in healthy working adults in Russia and the
economic beneﬁts of such a program from an employer perspec-
tive. METHODS: A prospective, non-randomized, non-placebo
cost-beneﬁt study was conducted involving two groups: vacci-
nated and non-vaccinated. A 9-month follow-up was done
(October 2005–May 2006) using different questionnaires: one at
inclusion to collect general employee information; an other one,
one week after vaccine injection to collect post-vaccination
adverse events; and the last questionnaire was used monthly to
collect Inﬂuenza Like Illness (ILI) events, duration of symptoms
and sick leave associated. Effectiveness calculations and cost-
beneﬁt analyses were performed to evaluate the impact of inﬂu-
enza vaccination program in optimizing the productivity of
employee and the return on investment for the employer.
RESULTS: In all, 1331 volunteers joined the study: 630 in the
vaccinated group and 701 in the non-vaccinated group. The
attack rate of ILI was lower among vaccinated (6.8%) than
non-vaccinated subjects (23.2%). The effectiveness rates of inﬂu-
enza vaccine have reached 70.4% in reducing ILI occurrence and
80.8% in reducing sick leave days. 5.4€ per employee were
invested for the vaccination. Assuming that employees working
while experiencing ILI symptoms have a reduced level of produc-
tivity (30 to 70% of normal), the mean cost of disease avoided
thanks to vaccination was between 7.5 and 10.8€. CONCLU-
SION: This study showed that ILI episodes had signiﬁcant
impact on work productivity. Inﬂuenza vaccination programs
can decrease this impact and leads to cost-saving for the
employer.
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OBJECTIVES: To perform a cost-beneﬁt analysis of oseltamivir
versus no antiviral treatment for Roche Brazil employees who
were infected with inﬂuenza during the year of 2006.
METHODS: A cost-beneﬁt model was developed to compare the
costs of two treatment alternatives; Oseltamivir and no antiviral
treatment for inﬂuenza. A decision-tree model based on O’Brian,
B. et al, 2003 was built to simulate the course of the inﬂuenza
infection. The number of workdays lost at Roche Brasil were
derived from a retrospective analysis based on patient records
and then compared with four different studies (Yoichiro et al.
2006, Rothberg, et al. 2005, Akazawa, et al. 2003 e Postma,
et al. 2005). A one-year timeframe was used for the comparison.
A total of 73 inﬂuenza cases were observed during the year of
2006 at Roche Brazil. Direct medical costs were obtained from
the HMO responsible for Roche employees. Indirect costs related
to absenteeism were based on a human capital approach consid-
ering the company expenses with personnel (salary + fringe ben-
eﬁts) as the workday value for each worker. Discounting was not
included due to the short-term perspective of the analysis.
RESULTS: Total costs were R$ 20,198 for oseltamivir treatment
group, and for the no antiviral treatment group total costs ranged
from R$ 41,062 to R$ 55,261 depending on the study utilized.
The cost-savings observed for oseltamivir were due to lower
absenteeism costs (diference between the two groups ranged
from from R$ 26,842 to R$ 41,040) and its less frequent disease
complications. Multi-way Sensitivity analyses conﬁrmed the
robustness of the results obtained. CONCLUSION: The analysis
suggests that providing oseltamivir would incur in a substantial
beneﬁt for the employer. It worth to remind that the size of the
beneﬁt is also related to the company’s health care program (e.g.
vaccination coverage).
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OBJECTIVES: Increasing rates of resistance to antimicrobial
therapy increase the risk of therapeutic failure and impose a
challenge on therapy of infections. Thereby, resistant microor-
ganisms lead to a signiﬁcant increase in patient morbidity, mor-
tality, and health care costs. Tigecycline, a glycylcycline, offers a
broad-spectrum of activity including resistant pathogens such as
methicillin-resistant Staphylococcus aureus (MRSA). In order to
assess the cost-effectiveness of Tigecycline vs. selected standard
antibiotics, we modeled its use in the treatment of complicated
intra-abdominal infections (cIAI). METHODS: A decision-
analytic model was developed and adapted to estimate expected
outcomes and costs of initial antibiotic therapy. Tigecycline
therapy was compared with ceftriaxone/metronidazole, cipro-
ﬂoxacin/metronidazole, imipenem/cilastatin and levoﬂoxacin/
metronidazole. We used published data on pathogen prevalence,
in-vitro eradication rates, length of stay (LOS), failure rates and
mortality in order to populate the model. Information on inpa-
tient costs and drug costs were derived from ofﬁcial databases.
RESULTS: Overall success rate of initial tigecycline therapy
was 89%. Ceftriaxone/metronidazole (71%), ciproﬂoxacin/
metronidazole (70%), imipenem (82%), levoﬂoxacin/
metronidazol (76%) showed lower suc-cess rates. LOS was
shortest with tigecycline therapy (13.8 d vs. 15.1, 15.1, 14.3,
14.7 respectively). Cost-effectiveness of tigecycline was better
than for all comparators (6631.76€ vs. 8542.42€, 9200.67€,
7251.55€ and 7925.48€ per treatment success). Tigecycline
therapy was dominant, e.g. it was more ef-fective than all other
regimens at lower total costs. CONCLUSION: The model indi-
cates that empirical therapy with tigecycline is more cost-effective
than standard antibiotic regimens.
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